Socratech L.L.C. is a biotechnology company with the primary focus on discovery and development of therapeutics for the treatment of neurodegenerative disorders such as Alzheimers disease and stroke. Alzheimer's disease is the fourth leading cause of death. Alzheimers Disease is a devastating brain disorder associated with fatal cognitive impairment, mental disability and progressive degeneration of brain cells in elderly population. Stroke is the third leading cause of death associated with degeneration of brain cells and neurological disabilities.
The major thrust in Socratech is the novel concept that vascular system plays a key role in initiating the pathology of brain cells and therefore represents a primary therapeutic target. The Nobel Prize Winner 2000, Dr Arvid Carlsson, the world-renowned neuroscientist, has commented on Socratech’s concept: “The role of vascular system in brain disorders has not been studied enough, and it would be of great importance to pursue these studies”.
Vascular system controls cerebral blood flow, transport of molecules across the blood-brain barrier including removal of critical toxins, and formation of new blood vessels during aging and neurodegenerative disorders. Socratech has strong expertise in studying vascular pathogenic mechanisms in Alzheimer’s disease and stroke, and is a pioneer in developing vascularly-based diagnostic tests and therapeutic strategies for brain disorders. Socratech’s portfolio comprises of new therapeutic approaches for vascular and brain cell protection, removal of Alzheimer’s toxin, diagnostic tests for Alzheimer’s disease, and identification of new diagnostic markers and molecular targets for treatment of Alzheimer’s disease.
As evidence of its quality programs, Socratech’s portfolio is based on research projects that have been awarded financial support from several leading organizations in the U.S.; the National Institute on Aging, the National Institute for Neurological Disorders & Stroke, the National Institute for Heart, Blood and Lung, and the MSZ Investments, Inc. Socratech has its own research group working on “Vascular Gene Discovery in Alzheimer’s Disease” sponsored by MSZ Investors. The company’s R & D center is in Rochester New York. Socratech has established collaborations with the University of Rochester Medical Center New York, the Scripps Research Institute La Jolla, the Keck School of Medicine University of Southern California Los Angeles, the College of Physicians and Surgeons of Columbia University New York, the School of Medicine at the SUNY Stony Brook and the Iowa University School of Medicine.
The fields in which Socratech is currently working are divided as follows:
(1) Activated protein C (APC) to treat neurodegenerative brain disorders,
(2) Protein S for protection of the nervous system from cell injury,
(3) New vascular gene targets for treatment and diagnosis of
brain disorders and cognitive impairments and development of new drugs(4) Clearance of Alzheimer's toxin amyloid-ß by LRP
Recent discussions of work done by Dr. Zlokovic, the chief scientific officer of Socratech as stated in University of Rochester Medical Center Newsletter:
Dr. Zlokovic investigates vascular mechanisms in two neurological diseases of enormous clinical and public health significance: Alzheimer's Disease and stroke. His work on Alzheimer's Disease earned him the MERIT award (pending an official award notice from NIH.) Betsa is pursuing an etiologic theory that has substantial therapeutic potential. This theory holds that accumulation of amyloid peptide (which I will call "amyloid"), the primary pathologic event in Alzheimer's Disease, is the result of disordered equilibrium in the flux of amyloid across the blood-brain barrier. Although there are skeptics who favor alternative views, Dr. Zlokovic has now developed many lines of experimental support for his case, leading to a growing consensus about the fundamental importance in Alzheimer's Disease of the amyloid-clearing phenomenon through the blood-brain barrier.
The overarching questions that Dr. Zlokovic and his collaborators are asking about Alzheimer's Disease are the most fundamental ones that one can ask about any disease: "What causes it?" and "If we can know the cause, does this lead to effective treatment?" To understand Betsa's approach, let me recount a few fundamental observations about Alzheimer's Disease: deposition of amyloid in the central nervous system is accelerated in Alzheimer's Disease; amyloid is neurotoxic, inducing oxidant stress in endothelial cells and causing synaptic dysfunction in the brains of AD patients and in AD animal models; transport of amyloid across the blood-brain barrier (BBB) plays a central role in determining concentrations of amyloid in the central nervous system (CNS); and finally, the BBB regulates entry of amyloid from the bloodstream into the CNS and clears brain-derived amyloid through specific receptors or carrier-mediated mechanisms.
Socratech Chief Scientific Officer:
Berislav V. Zlokovic, M.D., Ph.D.
Professor and Associate Chair, Neurosurgery
Director, F.P. Smith Laboratory for Neuroscience & Neurosurgery Research
Scientific Director, Socratech, L.L.C.
Kornberg Medical Research Bldg., Rm. #G-9613
601 Elmwood Avenue, Box 670
Rochester, New York 14642 email@example.com